What is Sales and Marketing Strategy of Shenzhen Mindray Bio-Medical Electronics Company?

For its more expensive, high-end medical equipment, Mindray maintains a direct sales network. This allows for cultivating deeper customer relationships and providing tailored solutions to meet specific client needs.

The company utilizes an extensive distributor-based system, particularly for lower-end products and to effectively penetrate diverse regional markets. This strategy was notably adopted around 2003 as global players shifted towards direct models.

Mindray's global reach is supported by 63 international subsidiaries in approximately 40 countries, complemented by 36 subsidiaries and over 30 branches within China. This forms a robust sales and service network.

In 2024, overseas revenue saw a significant increase of 21.3% year-over-year, reaching RMB 16.4 billion. This international segment contributed 44.7% to the company's total revenue, with high-end strategic customers accounting for 14% of this overseas figure.

Mindray's brand identity is built on the principle of making healthcare better and more accessible globally. This commitment guides its approach to developing and delivering medical technologies.

The consistent use of red, white, and gray in its visual identity conveys professionalism and reliability. The company's tone of voice reflects care for patients, physicians, and society, emphasizing a customer experience focused on quality and ease of use.

Mindray positions itself as a provider of valuable solutions that improve clinical outcomes and operational efficiency. This approach goes beyond simply selling medical devices, focusing on comprehensive support and enhancement of healthcare services.

The company's strategic focus on high-end markets and advanced solutions, such as the Resona series ultrasound systems, demonstrates a strong commitment to innovation and technological advancement in healthcare.

In November 2024, Mindray announced a strategic partnership with TeleRay. This collaboration aims to revolutionize ultrasound imaging delivery through Mindray's Resona 7 and Resona I9 Ultrasound Systems. The partnership leverages advanced medical image distribution software with telehealth technology for secure, real-time streaming, enhancing clinician efficiency and patient convenience.

Also in November 2024, a Strategic Cooperation Agreement was signed with the Medical Ultrasonic Society of Thailand (MUST). This campaign focuses on standardized ultrasound training, pre-launch evaluation of high-end products like the Resona A20, and academic exchange platforms. The goal is to improve medical equipment, academy, and services while promoting medical human resource training.

Mindray's participation in major industry events serves as ongoing campaign platforms. At ACEP 2024 (September-October 2024), the company showcased point-of-care ultrasound (POCUS) advancements and patient monitors for emergency medicine. At RSNA 2024 (December 2024), Mindray unveiled the Resona I8 Ultrasound Machine and announced its expansion into Digital Radiography, emphasizing comprehensive performance and workflow streamlining.

'Project 2025' is an overarching campaign engaging global experts in education, technology exchange, and research cooperation to advance ultrasound medicine. While specific campaign sales figures are not public, Mindray's overseas revenue saw a significant growth of 21.3% in 2024, indicating strong market reception to its global outreach and product launches, reflecting its robust Marketing Strategy of Shenzhen Mindray Bio-Medical Electronics.